2022 SOHO Annual Meeting
The 10th Annual Meeting of the Society of Hematologic Oncology was held from September 28–October 1, 2022, virtually and in-person in Houston, Texas.
Advertisement
Does the route of administration matter in preventing CNS relapse in agressive B-cell lymphomas?
Marina Konopleva, MD, PhD, discusses venetoclax resistance in AML during SOHO 2022
Jia Ruan, spoke on emerging treatment options for MCL in this interview from SOHO 2022.
A retrospective study observed a three-year OS rate of 66.7% in primary MF patients and 55.6% in secondary MF patients...
Gilteritinib plus induction and consolidation chemotherapy demonstrated acceptable safety outcomes.
Dr. Konopleva spoke to Blood Cancers Today during the 2022 SOHO Annual Meeting.
Dr. Coombs discussed these challenges during the 10th Annual Meeting of the Society of Hematologic Oncology.
Autologous chimeric antigen receptor (CAR) T-cell therapies have shown “unprecedented efficacy” in patients with ...
Carlos de Lima, MD, stopped by the Blood Cancers Today booth at the 2022 SOHO Annual Meeting to give his advice...
Event-free survival at 24 months may become an important clinical endpoint in mantle cell lymphoma in the future.
Tycel Phillips, MD, discusses the role of targeted therapies in frontline mantel cell lymphoma (MCL).
Jia Ruan, MD, PhD, discusses emerging treatment options for mantle cell lymphoma at the 2022 SOHO Annual Meeting.
The phase III BRUIN MCL-321 is currently enrolling patients to compare the efficacy of pirtobrutinib versus other BTKi.
Updated results from a phase I/IIb study demonstrated promising efficacy for the novel agent pirtobrutinib.
Catherine Coombs, MD, discusses Bruton’s tyrosine kinase inhibitors at the 2022 SOHO Annual Meeting.
Alexey V. Danilov, MD, PhD, spoke with Blood Cancers Today about his 2022 SOHO Annual Meeting presentation.
The use of extracorporeal photopheresis declined in patients with Sézary syndrome as the COVID-19 pandemic began.
The efficacy of enasidenib in patients with AML depends on the mutation type.
A conditioning regimen of clofarabine plus total body irradiation led to a two-year overall survival rate of 43%
Researchers investigated its use in patients undergoing mismatched donor HSCT with post-transplant cyclophosphamide...
Researchers had not previously studied the long-term impact of omidubicel...
New research suggests venetoclax-containing regimens with intensive treatment and may improve outcomes.
Blood Cancers Today Associate Editor Elias Jabbour, MD, gave his thoughts on the first day of the 2022 SOHO Annual Meeting.
Jennifer R. Brown, MD, PhD, talks about her plans for the presidency in the upcoming year at the 2022 SOHO Annual Meeting.
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, provides an update...
As treatments for CLL evolve, new challenges have arisen to address the disease’s resistance to targeted therapies.
Thomas Kipps, MD, PhD, was honored with the Michael J. Keating award from SOHO during its annual meeting.
Blood Cancers Today Associate Editor Jerald Radich, MD, discusses the role of ddPCR for CML in the age of targeted therapies.
SOHO President Moshe Talpaz, MD, shares how it feels to be back onsite for the Annual Meeting.
There was no significant difference between patients treated with azacitidine on a five-day or a five-plus-two-day schedule..
Of the dozens of posters that were displayed on the first evening of the SOHO Annual Meeting, eight were honored with awards.
The 2022 SOHO Annual Meeting kicked off with remarks from 2022-2023 President Moshe Talpaz, MD.
Guillermo Garcia-Manero, MD, gives his perspective.
Elias Jabbour, MD, shares what he is most looking forward to at the 2022 SOHO Annual Meeting.
Patients with CMML who received an allogeneic HSCT earlier in the course of their disease had better outcomes.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.